MedTrace Logo

Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine

NCT01380288 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2018-02-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate and compare the changes of cognitive function (as measured by ADAS-Cog) in the two group of patients with Alzheimer's disease (AD) associated with and without white matter changes after rivastigmine patch therapy.

Conditions

Interventions

DRUG

rivastigmine patch

rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks

Sponsors & Collaborators

  • Novartis Korea Ltd.

    collaborator INDUSTRY

  • Dong-A University

    lead OTHER

Principal Investigators

  • Kyung Won Park, MD, PhD · Dong-A University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2016-12-31
Completion
2017-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01380288 on ClinicalTrials.gov